Intellicheck Mobilisa, Inc. (NYSEMKT:IDN)’s stock surged 21.23% to $1.37. The company on Mar. 21 has doubled its sales force with the addition of five recent hires. In addition to the new hires, the company has restructured its sales force into vertical markets. Ms. Elizabeth (Beth) Quinn, Vice President of Sales, Retail & Hospitality and Mr. Charles Weiss, Vice President of Sales, Financial join Mr. Larry McGonagle, Vice President of Sales, Commercial in the Long Island office. On last trading day Intellicheck Mobilisa, Inc. (NYSEMKT:IDN) ended up 44.25% higher to close at $1.63 while trading in the range of $1.21 – $1.79. Its return on assets (ROA) is -24.10% while return on investment (ROI) is -13.00%. Intellicheck Mobilisa, Inc. (NYSEMKT:IDN) monthly performance is 103.75%.
Microvision (NASDAQ:MVIS) was up big yesterday, after the tiny tech company announced a deal with UPS. And Pandora stock took a hit, just two days after the Internet radio giant announced it will raise subscription fees because of the rising cost of music. Microvision, Inc. (NASDAQ:MVIS) in last trading activity ended up at $2.38 with day range of $2.24 – $2.80. Company weekly performance is 16.91% while its quarterly performance stands at 118.81%. Microvision, Inc. (NASDAQ:MVIS) is -31.66% away from its 52 week high.
Herbalife Ltd. (NYSE:HLF) wants Carl Icahn aboard, and if all goes its way Mr. Icahn will soon control 5 of the company’s 13 board seats (38%+), while owning just under 17% of the company’s stock. Herbalife Ltd. (NYSE:HLF) belongs to Consumer Goods sector with market capitalization of 5.35 B and has 1.40% insider ownership. In last trading activity company’s stock closed at $52.86 while opening price was $52.75.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced that two oral presentations were made at the 23rd Asian Pacific Association for the Study of the Liver (APASL) Conference 2014 in Brisbane, Australia. Updated Phase 2 clinical trial results evaluating a 150 mg loading dose followed by 50 mg once daily of ACH-3102 in combination with either once daily 200 mg or 400 mg of sovaprevir and twice daily ribavirin showed that 100% of patients achieved SVR12 (n=8) including subjects who had Y93 mutations at baseline. On Monday shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) opened at $3.63 and closed at $3.61. This year Company’s Earnings per Share (EPS) growth is 1.60% and next year’s estimated EPS growth is -11.50%. Analysts mean target price for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is $4.94.
Leave a Reply